Business Context and Reporting Period
This Form 8-K Current Report was filed by Quanterix Corporation on May 10, 2021, regarding events occurring on May 11, 2021. The filing discloses the appointment of Masoud Toloue as President of Quanterix Corporation and Diagnostics, effective June 9, 2021. Dr. Toloue joins the company from PerkinElmer, where he most recently served as Senior Vice President, Diagnostics.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change is the appointment of new executive leadership. Dr. Toloue's employment agreement includes the following compensation terms:
- Base Salary: $525,000 annualized.
- Performance Bonus: Target of up to $525,000 annually (2021 bonus prorated based on actual salary earned).
- Sign-On Equity: 50,703 restricted stock units vesting over three years (one-third on the first anniversary, remainder monthly).
- Sign-On Cash: $100,000 payable shortly after the start date.
- Future Equity: Eligible for annual grants with a target fair value of up to $1,600,000 starting in the 2022 cycle.
Outlook, Risks, and Contingencies
The filing outlines specific severance and change-in-control provisions:
- Termination without Cause/Good Reason: Entitles Dr. Toloue to 12 months of base salary, the annual target bonus, acceleration of equity that would have vested during the severance period, and health benefits continuation.
- Change-in-Control: Triggers full acceleration of all outstanding unvested equity awards if employment is terminated without cause or resignation for good reason.
- Conditions: Receipt of termination benefits requires the execution of a separation agreement including restrictive covenants and a general release of claims.
Investor Verification Checklist
- Verify the exact vesting schedule and cliff provisions for the 50,703 restricted stock units in the attached Employment Agreement (Exhibit 10.1).
- Confirm the specific performance metrics used to calculate the annual bonus target.
- Review the definition of "Good Reason" and "Without Cause" within the Employment Agreement to understand severance triggers.
- Assess the impact of the $100,000 sign-on cash payment and future equity grants on the company's cash flow and dilution.